Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer
Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer
复制标题
DOI：
10.1002/hed.24125
复制
发表时间：
2016-04-01
影响因子：
2.9
通讯作者：
Tao, Yungan
中科院分区：
文献类型：
--
作者：
Levy, Antonin;De Felice, Francesca;Tao, Yungan
背景。本研究的目的是评估头颈鳞状细胞癌 (HNSCC) 紫杉烷类诱导化疗后同步放疗和西妥昔单抗（生物放疗 [BRT]）的耐受性。方法。 104 名 HNSCC 患者接受了 BRT（29%）或未接受基于紫杉烷的诱导化疗（71%）。结果。放射性皮炎（97%）和皮疹（65%）经常发生，但在两个人群中观察到的皮疹发生率或级别没有差异。然而，与未进行诱导化疗的患者相比，接受基于紫杉烷的诱导化疗的患者皮疹的严重程度较轻。粘膜炎和吞咽困难在两组中均常见且具有可比性。皮疹（任何级别）的发生并不能预测总体生存率（OS）的增加，但它与接受基于紫杉烷类诱导化疗的患者的 3 年 OS 改善相关。在 2 个治疗亚组的总体人群中，OS 不受皮疹分级的影响。结论。基于紫杉烷的诱导化疗不会增加西妥昔单抗相关毒性的发生率。 (c) 2015 年 Wiley 期刊公司。
Background. The purpose of this study was to evaluate the tolerability of concurrent radiotherapy and cetuximab (bioradiotherapy [BRT]) after taxane-based induction chemotherapy in head and neck squamous cell carcinoma (HNSCC).Methods. One hundred four patients with HNSCC received BRT with (29%) or without (71%) prior taxane-based induction chemotherapy.Results. Radiodermatitis (97%) and skin rash (65%) occurred frequently, but there was no difference of occurrence or the grade of the rash observed in the 2 populations. However, patients receiving taxane-based induction chemotherapy had a less severe rash as compared with patients without induction chemotherapy. Mucositis and dysphagia were frequent and comparable in the 2 groups. The occurrence of a skin rash (at any grade) did not predict an increased overall survival (OS) in the overall population, but it was associated with an improved 3-year OS in patients receiving taxane-based induction chemotherapy. OS was not influenced by the skin rash grade in the overall population of the 2 treatment subgroups.Conclusion. Taxane-based induction chemotherapy did not increase the rate of cetuximab-related toxicities. (c) 2015 Wiley Periodicals, Inc.